163969 20260418110658.0 doi 10.1111/bju.70010 sideral 146093 ART-2026-146093 eng Rubio-Briones, José External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management 2026 Objectives To conduct an external multicentre validation to evaluate Uromonitor®‐version 2 (v2; U‐monitor, Porto, Portugal) as a biomarker for detecting non‐muscle‐invasive bladder cancer (NMIBC) recurrence in an independent patient cohort in a real‐world‐evidence setting and compare it to cytology. Patients and Methods The ‘External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group’ (EVALUATION‐CUETO) study is a prospective, multicentre, observational study (NCT05864599) conducted in Spain. Inclusion criteria included any risk group of patients with NMIBC undergoing follow‐up. The most recent (index) NMIBC tumours of any grade had to have been diagnosed within the past 3 months to 2 years. Regarding biomarkers, data from cystoscopy, cytology, and the Uromonitor‐v2 test were collected. Predictive performance parameters, including accuracy, area under the curve, negative and positive predictive values (NPV, PPV), sensitivity, and specificity, were calculated. Results A total of 1178 patients with a mean age of 72 years and a predominant male representation (80%) were included. Among the positive Uromonitor-v2 cases, 64 (57.66%) exhibited a TERT promoter mutation, and 59 (53.15%) harboured a FGFR3 mutation. No KRAS mutations were found. For the total population, Uromonitor-v2 demonstrated high specificity (0.93) and NPV (0.93), but low sensitivity (0.36) and PPV (0.36), indicating a limited ability to detect all recurrences and confirm positive cases. Performance varied across tumour grades, with low-grade tumours showing a low sensitivity of 0.32 and high-grade tumours achieving a higher but insufficient sensitivity of 0.44. Specificity remained consistent at 0.93 across all groups. Uromonitor-v2 achieved higher accuracy compared to cytology alone, with the combined approach further improving overall predictive performance. Conclusion The strong specificity and NPV observed across all studies suggest a role of Uromonitor‐v2 as a potential tool for NMIBC follow‐up, particularly in ruling out recurrence and clarifying doubtful cystoscopy results. However, the unexpectedly low sensitivity reported in this external multicentre validation suggests the need for further investigation before routine clinical implementation. info:eu-repo/semantics/closedAccess All rights reserved http://www.europeana.eu/rights/rr-f/ info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Guerrero Ramos, Félix Mercadé Sánchez, Asier Bezana Abadía, Inés Martín Rodríguez, Ruth Alcaraz, Antonio Miqueleiz Legaz, Maite Lozano, Fernando Arrabal Martín, Miguel Luis Cardo, Adrián Gonzalo Rodríguez, Victoria Caño Velasco, Jorge Serrano Liesa, Miriam Ferreiro Pareja, Cristina Espílez Ortiz, Raquel Universidad de Zaragoza González-Valcárcel de Torres, Ignacio de Sánchez Zalabardo, Daniel Esquinas, Cristina Mengual, Lourdes Borque-Fernando, Angel Universidad de Zaragoza (orcid)0000-0003-0178-4567 Esteban Escaño, Luis Mariano (orcid)0000-0002-3007-302X Palou Redorta, Joan Witjes, Fred Martínez Piñeiro, Luis 1013 817 Universidad de Zaragoza Dpto. Cirugía Área Urología 137, 1 (2026), 216-224 BJU int. BJU international 1464-4096 630512 http://zaguan.unizar.es/record/163969/files/texto_completo.pdf Versión publicada info:eu-repo/date/embargoEnd/2026-10-01 2795403 http://zaguan.unizar.es/record/163969/files/texto_completo.jpg?subformat=icon icon Versión publicada info:eu-repo/date/embargoEnd/2026-10-01 oai:zaguan.unizar.es:163969 articulos driver 2026-04-18-11:05:07 ARTICLE